EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

SGLT2 inhibitor use is associated with more polycythemia vera diagnosis codes but not with JAK2-positive polycythemia vera: a propensity score–matched cohort study

Alena Kirzhner, Martin Ellis, Maya Berla, Haitham Abu Khadija, Hefziba Green, Dan Haberman, Meital Zikry Deitch, Tal Schiller

Frontiers in Endocrinology · 03.11.2026 · 17

DOI: 10.3389/fendo.2026.1979710 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Endocrinology, online erschienen am 03.11.2026. Verfasst von Alena Kirzhner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine A, Kaplan Medical Center, Rehovot and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Polycythemia Vera, Janus Kinase 2, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2is) is associated with modest increases in hematocrit, which may prompt hematologic evaluation. We examined whether SGLT2i use is associated with increased detection of previously unrecognized myeloproliferative neoplasms (MPNs) and compared diagnosis code–based with JAK2 -positive ascertainment of polycythemia vera (PV).

Methods

We conducted a retrospective cohort study using electronic health records from Clalit Health Services, including adults aged ≥40 years with diabetes who initiated SGLT2is or dipeptidyl peptidase-4 inhibitors (DPP4is) between January 2015 and July 2025, with follow-up through November 2025. Baseline clinical, laboratory, and medication data were collected, and participants were followed for incident MPNs. SGLT2i users were matched 1:1 to DPP4i users using propensity scores. Hazard ratios (HRs) were estimated using Cox and Fine–Gray competing-risk models.

Results

A total of 73,147 SGLT2i and 48,639 DPP4i users were eligible. After propensity score matching, 40,550 patients remained in each group, with balance across most baseline characteristics; residual creatinine imbalance was addressed in an extended model. Median follow-up was 3.8 years with SGLT2is and 7.0 years with DPP4is. A new PV diagnosis code (ICD-10 D45) was recorded in 204 SGLT2i users and 205 DPP4i users [1.22 vs. 0.76 per 1,000 person-years; adjusted HR (aHR) 1.69, 95% confidence interval (CI) 1.39–2.05], with the excess concentrated in the first year after initiation. Among the 204 patients who underwent JAK2 testing, 64 (31.4%) had a positive result, representing 15.6% of all 409 patients with a D45 code. JAK2 positivity among tested patients was lower with SGLT2is than DPP4is (24.5% vs. 37.7%). JAK2 -positive coded PV was identified in 24 and 40 patients, respectively (0.14 vs. 0.15 per 1,000 person-years; aHR 1.00, 95% CI 0.60–1.65). No significant differences were observed for essential thrombocythemia or primary myelofibrosis. Results were consistent in competing-risk and sensitivity analyses.

Conclusions

SGLT2i use was associated with more PV diagnosis codes but not with JAK2 -positive PV or other MPNs. The findings are consistent with increased diagnostic evaluation of SGLT2i-related erythrocytosis rather than increased occurrence of clonal PV. Diagnosis codes alone may substantially overestimate confirmed disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycythemia VeraJanus Kinase 2Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansFemaleRetrospective StudiesMiddle AgedMaleAgedPropensity ScoreDipeptidyl-Peptidase IV InhibitorsAdultFollow-Up Studies

Stichwörter der Autor:innen

DPP4 inhibitorJAK2MPNSGLT2 inhibitordiabetesmyeloproliferative neoplasmspolycythemia vera

Substanzen

Janus Kinase 2Sodium-Glucose Transporter 2 InhibitorsJAK2 protein, humanDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine A, Kaplan Medical Center, Rehovot and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Institute of Hematology and Blood Bank, Meir Medical Center, Kfar Saba and Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Cardiology, Kaplan Medical Center, Rehovot and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Intensive Care Unit, Kaplan Medical Center, Rehovot and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Diabetes, Endocrinology, and Metabolic diseases, Wolfson Medical Center, Holon and Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Zitieren

APA

Kirzhner, A., Ellis, M., Berla, M., Abu Khadija, H., Green, H., Haberman, D., Zikry Deitch, M., & Schiller, T. (2026). SGLT2 inhibitor use is associated with more polycythemia vera diagnosis codes but not with JAK2-positive polycythemia vera: a propensity score–matched cohort study. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1979710

Vancouver

Kirzhner A, Ellis M, Berla M, Abu Khadija H, Green H, Haberman D, et al. SGLT2 inhibitor use is associated with more polycythemia vera diagnosis codes but not with JAK2-positive polycythemia vera: a propensity score–matched cohort study. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1979710

BibTeX
@article{Kirzhner2026,
  author = {Kirzhner, Alena and Ellis, Martin and Berla, Maya and Abu Khadija, Haitham and Green, Hefziba and Haberman, Dan and Zikry Deitch, Meital and Schiller, Tal},
  title = {SGLT2 inhibitor use is associated with more polycythemia vera diagnosis codes but not with JAK2-positive polycythemia vera: a propensity score–matched cohort study},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fendo.2026.1979710}
}
Kostenlos starten →